Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | President and COO | September 14, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,387 |
Last balance in matching sequence
After 2026-09-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-14 · Purchase · Acquired 1,800 · Balance 40,114 F1: This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. F2: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015; F3: (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and F4: (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person. F5: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. Row 2 · 2026-09-14 · Purchase · Acquired 273 · Balance 40,387 F1: This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. F2: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015; F3: (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and F4: (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person. F5: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.
F2: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;
F3: (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and
F4: (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.
F5: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 29, 2018 Filed Aug 31, 2018 19:35 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 20,000 | $14.00 | $280,000.00 |
DisclosureSEC source: 0001144204-18-047558 · tv502184_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,768 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 25,334 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 88,454 shares of common stock owned by the reporting person. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 19:35 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 20,000 | $3.45 | $69,000.00 |
DisclosureSEC source: 0001144204-18-047558 · tv502184_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 20:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 9,565 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001144204-18-047340 · tv502082_4.xml · derivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,300 Underlying: Common Stock · 9,565 shares Expires 2020-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 20:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 9,565 | $13.00 | $124,345.00 |
DisclosureSEC source: 0001144204-18-047340 · tv502082_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,768 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 25,334 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 88,454 shares of common stock owned by the reporting person. Read SEC document |
| August 28, 2018 Filed Aug 30, 2018 20:01 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 9,565 | $3.75 | $35,868.75 |
DisclosureSEC source: 0001144204-18-047340 · tv502082_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 7,600 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001144204-18-042169 · tv500216_4.xml · derivative · entry 6 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,865 Underlying: Common Stock · 7,600 shares Expires 2020-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 7,600 | $13.08 | $99,408.00 |
DisclosureSEC source: 0001144204-18-042169 · tv500216_4.xml · nonDerivative · entry 4 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,768 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.35. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 25,334 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 88,454 shares of common stock owned by the reporting person. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 7,600 | $3.45 | $26,220.00 |
DisclosureSEC source: 0001144204-18-042169 · tv500216_4.xml · nonDerivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 2,835 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001144204-18-042169 · tv500216_4.xml · derivative · entry 5 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,465 Underlying: Common Stock · 2,835 shares Expires 2020-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 2,835 | $13.00 | $36,855.00 |
DisclosureSEC source: 0001144204-18-042169 · tv500216_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,768 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 21:21 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 2,835 | $3.45 | $9,780.75 |
DisclosureSEC source: 0001144204-18-042169 · tv500216_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · derivative · entry 9 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2018-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,633 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · derivative · entry 8 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,300 Underlying: Common Stock · 8,633 shares Expires 2020-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Tax withholdingCommon Stock | 15,215 | $12.35 | $187,905.25 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · nonDerivative · entry 6 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,768 F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 25,334 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 88,454 shares of common stock owned by the reporting person. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 8,633 | $12.00 | $103,596.00 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · nonDerivative · entry 5 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,983 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 40,000 | $0.88 | $35,000.00 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · nonDerivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 8,633 | $3.75 | $32,373.75 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 11,367 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · derivative · entry 7 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,933 Underlying: Common Stock · 11,367 shares Expires 2020-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · derivative.exercise_date: These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 11,367 | $12.00 | $136,404.00 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · nonDerivative · entry 4 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,616 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 22:14 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 11,367 | $3.75 | $42,626.25 |
DisclosureSEC source: 0001144204-18-034653 · tv496714_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 17, 2018 Filed May 18, 2018 18:47 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001144204-18-029785 · tv494618_4.xml · derivative · entry 6 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 20,000 shares Expires 2018-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 17, 2018 Filed May 18, 2018 18:47 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001144204-18-029785 · tv494618_4.xml · derivative · entry 5 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2019-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 17, 2018 Filed May 18, 2018 18:47 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 20,000 | $10.00 | $200,000.00 |
DisclosureSEC source: 0001144204-18-029785 · tv494618_4.xml · nonDerivative · entry 4 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,551 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and (iii) 52,904 shares of common stock owned by the reporting person. Read SEC document |
| May 17, 2018 Filed May 18, 2018 18:47 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 8,000 | $10.00 | $80,000.00 |
DisclosureSEC source: 0001144204-18-029785 · tv494618_4.xml · nonDerivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,551 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 17, 2018 Filed May 18, 2018 18:47 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 20,000 | $0.88 | $17,500.00 |
DisclosureSEC source: 0001144204-18-029785 · tv494618_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 17, 2018 Filed May 18, 2018 18:47 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 8,000 | $4.20 | $33,600.00 |
DisclosureSEC source: 0001144204-18-029785 · tv494618_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 16, 2018 Filed May 18, 2018 18:45 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,846 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001144204-18-029783 · tv494617_4.xml · derivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 4,846 shares Expires 2018-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 16, 2018 Filed May 18, 2018 18:45 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 4,846 | $9.00 | $43,614.00 |
DisclosureSEC source: 0001144204-18-029783 · tv494617_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,551 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and (iii) 52,904 shares of common stock owned by the reporting person. Read SEC document |
| May 16, 2018 Filed May 18, 2018 18:45 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 4,846 | $0.88 | $4,240.25 |
DisclosureSEC source: 0001144204-18-029783 · tv494617_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:53 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,154 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001144204-18-029453 · tv494475_4.xml · derivative · entry 6 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,846 Underlying: Common Stock · 3,154 shares Expires 2018-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:53 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001144204-18-029453 · tv494475_4.xml · derivative · entry 5 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 4,000 shares Expires 2019-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:53 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 3,154 | $9.00 | $28,386.00 |
DisclosureSEC source: 0001144204-18-029453 · tv494475_4.xml · nonDerivative · entry 4 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,551 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and (iii) 52,904 shares of common stock owned by the reporting person. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:53 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 4,000 | $9.00 | $36,000.00 |
DisclosureSEC source: 0001144204-18-029453 · tv494475_4.xml · nonDerivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,705 F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:53 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 3,154 | $0.88 | $2,759.75 |
DisclosureSEC source: 0001144204-18-029453 · tv494475_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:53 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 4,000 | $4.20 | $16,800.00 |
DisclosureSEC source: 0001144204-18-029453 · tv494475_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 00:52 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 110,350 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001144204-18-015718 · tv488964_4.xml · derivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,350 Underlying: Common Stock · 110,350 shares Expires 2028-03-15 F3 · derivative.exercise_date: Such options were granted pursuant to the Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of the Company. Read SEC document |
| March 15, 2018 Filed Mar 20, 2018 00:52 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 10,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-015718 · tv488964_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,551 F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and (iii) 52,904 shares of common stock owned by the reporting person. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 23:44 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 89,250 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001144204-18-012636 · tv487685_form4.xml · derivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,250 Underlying: Common Stock · 89,250 shares Expires 2027-02-24 F1 · derivative.exercise_date: On February 24, 2017, the reporting person was granted an option to purchase 105,000 shares of Common Stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"), which was to vest upon achievement of certain performance goals as determined in the discretion of the Compensation Committee of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on February 28, 2017. On February 28, 2018, the Compensation Committee of the Board of Directors of the Company determined that 85% of such performance criteria was achieved during 2017, resulting in vesting of 89,250 shares underlying this option. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 23:44 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-012636 · tv487685_form4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,451 F2 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F3 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016 and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof , (b) 7,667 of the RSUs granted on June 7, 2016 and unvested as of the date hereof and (c) 38,000 RSUs granted on February 28, 2018 and reported on this Form 4 and (iii) 52,904 shares of common stock owned by the reporting person. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:23 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001144204-18-002684 · tv483558_4.xml · derivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2018-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:23 UTC | Cytosorbents Corp CTSO · Entity 7625 | Tax withholdingCommon Stock | 35,257 | $7.80 | $275,004.60 |
DisclosureSEC source: 0001144204-18-002684 · tv483558_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,805 F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 35,938 RSUs granted on February 24, 2017 and (b) 23,000 RSUs granted on June 7, 2016, and (iii) 27,967 shares of common stock owned by the reporting person. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 22:23 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 44,000 | $6.25 | $275,000.00 |
DisclosureSEC source: 0001144204-18-002684 · tv483558_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2017 Filed Dec 8, 2017 21:12 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001144204-17-062984 · tv481084_4.xml · derivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 4,000 shares Expires 2019-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2017 Filed Dec 8, 2017 21:12 UTC | Cytosorbents Corp CTSO · Entity 7625 | Exercise / conversionCommon Stock | 4,000 | $4.20 | $16,800.00 |
DisclosureSEC source: 0001144204-17-062984 · tv481084_4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 35,938 RSUs granted on February 24, 2017 and (b) 23,000 RSUs granted on June 7, 2016, and (iii) 19,224 shares of common stock owned by the reporting person. Read SEC document |
| November 27, 2017 Filed Dec 8, 2017 21:12 UTC | Cytosorbents Corp CTSO · Entity 7625 | SaleCommon Stock | 4,000 | $7.00 | $28,000.00 |
DisclosureSEC source: 0001144204-17-062984 · tv481084_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,062 Read SEC document |
| June 08, 2017 Filed Jun 8, 2017 22:38 UTC | Cytosorbents Corp CTSO · Entity 7625 | PurchaseCommon Stock | 2,500 | $4.00 | $10,000.00 |
DisclosureSEC source: 0001144204-17-031786 · v468721_4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,062 F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 35,938 RSUs granted on February 24, 2017 and (b) 23,000 RSUs granted on June 7, 2016 and (iii) 19,224 shares of common stock owned by the reporting person (including 2,500 shares of common stock purchased in the open market on June 8, 2017 and reported on this Form 4). Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:23 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001144204-17-011844 · v460713_form4.xml · derivative · entry 3 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2027-02-24 F5 · derivative.exercise_date: Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:23 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 17,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011844 · v460713_form4.xml · nonDerivative · entry 2 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,562 F3 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan. F4 · balance_after: Includes (i) 17,900 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 54,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (3) above, (iii) 125,000 restricted stock units granted on April 8, 2015, subject to vesting in accordance with the schedule set forth in (3) above and (iii) the restricted stock units described in (2) above. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:23 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantCommon Stock | 35,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-011844 · v460713_form4.xml · nonDerivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,662 F1 · shares: These shares represent restricted stock units which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 35,938 restricted stock units granted on February 24, 2017 and reported on this Form 4, (ii) 23,000 restricted stock units granted on June 7, 2016, subject to vesting in accordance with the schedule set forth in (1) above and (iii) 16,724 shares of common stock owned by the reporting person. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 20:55 UTC | Cytosorbents Corp CTSO · Entity 7625 | GrantStock Option (right to buy) · Derivative | 73,200 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001144204-17-005348 · v458130_4.xml · derivative · entry 1 Capponi Vincent · CIK 0001368151 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,200 Underlying: Common Stock · 73,200 shares Expires 2026-06-07 F1 · derivative.exercise_date: On June 7, 2016, the reporting person was granted an option to purchase 91,500 shares of common stock pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, which was to vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation (the "Company"). This grant was reported on a Form 4 filed on June 9, 2016. On January 30, 2017, the Board of Directors of the Company determined that 80% of such performance criteria was achieved during 2016, resulting in the vesting of 73,200 shares underlying this option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.